RxDoctor Payments Data

Taylor Kirkman, DO

Interventional Cardiology · New Bern, NCNPI 1740635366

Payments from drug & device makers

$12,541in general payments, 2019–2025

Across 267 payments — averaging $46.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Edwards Lifesciences$2K
  • Boston Scientific$1K
  • Inari Medical, Inc.$1K
  • Medtronic$1K
  • Cardiovascular Systems Inc.$936
  • plus $4K from 30 others

What the payments were for

  • Travel & lodging$2,05416%
  • Food & beverage$10,06180%
  • Education$4263%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,541 in reported general payments places this provider in the 55th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$212,785
Medicare patients
705
Services billed
3,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$42,085
FarxigaDapagliflozin Propanediol27$19,181
EntrestoSacubitril/Valsartan13$18,227
JardianceEmpagliflozin14$16,969
XareltoRivaroxaban15$14,925
Repatha SureclickEvolocumab20$12,456
BrilintaTicagrelor12$6,094
Metoprolol Succinate98$1,616
ClopidogrelClopidogrel Bisulfate95$1,006
Atorvastatin Calcium93$959
Nitroglycerin32$922
Rosuvastatin Calcium85$875
Carvedilol83$812
Isosorbide Mononitrate ErIsosorbide Mononitrate73$676
Furosemide108$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$42,08543 claims
AstraZenecaFarxiga, Brilinta$239$25,27539 claims
NovartisEntresto$164$18,22713 claims
Boehringer IngelheimJardiance$13$16,96914 claims
Johnson & JohnsonXarelto$269$14,92515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →